atorvastatin has been researched along with cardiovascular agents in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (33.33) | 29.6817 |
| 2010's | 19 (52.78) | 24.3611 |
| 2020's | 5 (13.89) | 2.80 |
| Authors | Studies |
|---|---|
| Lewin, JJ; Nappi, JM; Taylor, MH | 1 |
| Ammirati, F; Colivicchi, F; Guido, V; Montefoschi, N; Santini, M; Tubaro, M; Varveri, A | 1 |
| Malik, P | 1 |
| Daida, H; Kurata, T; Miyauchi, K; Okazaki, S; Sato, H; Shimada, K; Yokoyama, T | 1 |
| Courtney, BK; Fitzgerald, PJ; Koizumi, T; Komiyama, N; Komuro, I; Kuriyama, N; Nakayama, T; Nameki, M; Namikawa, S; Yokoyama, M | 1 |
| Di Sciascio, G; Pasceri, V; Patti, G | 1 |
| Andrade, RJ; Barriocanal, A; Borraz, Y; Costa, J; Durán, JA; Fernández, MC; García-Cortés, M; García-Muņoz, B; Guarner, C; Hidalgo, R; Kaplowitz, N; Lucena, MI; Muņoz-Yagüe, T; Pachkoria, K; Pelaez, G; Planas, R; Rodrigo, L; Romero-Gomez, M; Salmerón, J | 1 |
| Fukunami, M; Kioka, H; Masuda, M; Mine, T; Morita, T; Node, K; Okuda, K; Tamaki, S; Tsukamoto, Y; Yamada, T | 1 |
| Braunwald, E | 1 |
| Horwich, TB; MacLellan, WR | 1 |
| Kumar, V; Shah, RP; Singh, S | 1 |
| Kitas, GD; Melas, N; Saratzis, A; Saratzis, N | 1 |
| Bahcivan, M; Erenler, BH; Gol, MK; Keceligil, HT; Kolbakir, F; Yucel, S | 1 |
| Chen, G; Deng, CQ; Wu, L | 1 |
| Chedgy, F; Howlett, DC; Inglis, C | 1 |
| Corcione, N; Di Pace, AL; Ferraro, P; Giordano, A; Monaco, M; Nappo, G; Polimeno, M; Romano, MF; Romano, S; Sorrentino, A | 1 |
| Lazareva, NV; Oshchepkova, EV | 1 |
| Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL | 1 |
| Davutoglu, V; Ercan, S; Sari, I | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C | 1 |
| Huo, Y; Peng, DQ; Yu, BL; Zhao, SP | 1 |
| Cheng, KK; Etemadi, A; Hemming, K; Jaafari, E; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marjani, H; Marshall, T; Merat, S; Mohammadifard, N; Naemi, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Sadeghi, M; Sarrafzadegan, N; Thomas, GN | 1 |
| Bonham, L; Donnelly, RF; Hughes, CM; Quinn, HL | 1 |
| Ceron, CS; Gerlach, RF; Guimarães, DA; Martins-Oliveira, A; Rizzi, E; Shiva, S; Tanus-Santos, JE | 1 |
| Castellano, JM; Fuster, V; Tamargo, J | 1 |
| Einecke, D | 1 |
| Stiefelhagen, P | 1 |
| Abarca, B; Alemán, JJ; Baron-Esquivias, G; Egocheaga, I; Galve, E; Garcia-Moll, FX; González-Juanatey, JR; Lidón, RM; Llisterri, JL; Lobos, JM; Millán, J; Mostaza, JM; Pallares, V; Sánchez, PL; Suárez, C | 1 |
| Lapa, T; Montenegro Sá, F; Simões, I; Vieira Marques, F | 1 |
| Andrés Marín, N; Antigüedad-Muñoz, J; Arenaza Choperena, G; de la Riva, P; Fernández-Eulate, G; Martínez Zabaleta, M; Moreno Valladares, M; Muñoz Lopetegi, A | 1 |
| Boffetta, P; Brennan, P; Cheng, KK; Etemadi, A; Fazel, A; Gharavi, A; Hemming, K; Kamangar, F; Khoshnia, M; Majed, M; Malekzadeh, F; Malekzadeh, R; Marshall, T; Merat, S; Mohammadifard, N; Naemi-Tabiei, M; Nalini, M; Nateghi, A; Navabakhsh, B; Ostovaneh, MR; Pourshams, A; Poustchi, H; Roshandel, G; Sadeghi, M; Sarrafzadegan, N; Thomas, N | 1 |
| Battegay, M; Cavassini, M; Courlet, P; Decosterd, L; Marzolini, C; Saldanha, SA; Stader, F; Stoeckle, M | 1 |
| Gao, Z; Lin, H; Lin, W; Liu, A; Ping, S; Ren, Y | 1 |
| Li, Z; Tu, Y; Zhang, J; Zhang, M; Zhou, Q; Zong, W | 1 |
| Abdallah, NA; El-Awady, MI; El-Brashy, AM; Ibrahim, FA | 1 |
| Abramson, JS; Armand, P; Asnani, A; Barnes, JA; Brahmbhatt, P; Drobni, ZD; Friedman, RS; Gilman, HK; Han, Y; Heemelaar, JC; Ho, JS; Hochberg, EP; Hua, L; Jacobsen, ED; Jacobson, CA; Januzzi, JL; Jerosch-Herold, M; Kim, AI; Kwong, RY; Ky, B; Lacasce, AS; Landsburg, D; Mahmood, SS; Mousavi, N; Nasta, S; Neilan, TG; Neuberg, DS; Onoue, T; Quinaglia, T; Redd, RA; Sama, S; Scherrer-Crosbie, M; Smith, A; Soumerai, JD; Svoboda, J | 1 |
3 review(s) available for atorvastatin and cardiovascular agents
| Article | Year |
|---|---|
Atorvastatin and statins in the treatment of heart failure.
Topics: Animals; Atorvastatin; Cardiovascular Agents; Drug Interactions; Heart Failure; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Pyrroles; Treatment Outcome | 2007 |
Can statins suppress the development of abdominal aortic aneurysms? A review of the current evidence.
Topics: Animals; Aortic Aneurysm, Abdominal; Atorvastatin; Blood Vessels; Cardiovascular Agents; Disease Progression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Matrix Metalloproteinases; Models, Animal; Pyrroles; Risk Assessment; Simvastatin | 2010 |
The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Ramipril; Secondary Prevention | 2015 |
9 trial(s) available for atorvastatin and cardiovascular agents
| Article | Year |
|---|---|
Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Anticholesteremic Agents; Atorvastatin; Cardiovascular Agents; Drug Therapy, Combination; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pyrroles; Recurrence; Survival Rate | 2002 |
Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study.
Topics: Acute Disease; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atorvastatin; Cardiovascular Agents; Cholesterol, LDL; Cilostazol; Combined Modality Therapy; Coronary Angiography; Coronary Disease; Female; Follow-Up Studies; Heparin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Platelet Aggregation Inhibitors; Prospective Studies; Pyrroles; Tetrazoles; Ticlopidine; Treatment Outcome; Ultrasonography, Interventional | 2004 |
Plasma low-density lipoprotein reduction and structural effects on coronary atherosclerotic plaques by atorvastatin as clinically assessed with intravascular ultrasound radio-frequency signal analysis: a randomized prospective study.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Atorvastatin; Cardiovascular Agents; Cholesterol, LDL; Comorbidity; Coronary Artery Disease; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Prospective Studies; Pyrroles; Radio Waves; Single-Blind Method; Treatment Outcome; Ultrasonography, Interventional | 2005 |
Prevention of myocardial damage during coronary intervention.
Topics: Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Biomarkers; Cardiovascular Agents; Double-Blind Method; Drug Administration Schedule; Female; Heptanoic Acids; Humans; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Pyrroles; Treatment Outcome | 2006 |
Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
Topics: Aged; Atorvastatin; Baroreflex; Body Mass Index; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Diet, Fat-Restricted; Dyslipidemias; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Obesity; Patient Dropouts; Prospective Studies; Pyrroles; Risk Factors | 2014 |
The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; C-Reactive Protein; Cardiovascular Agents; China; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Prospective Studies; Pyrroles; Treatment Outcome | 2014 |
Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Clinical Protocols; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Iran; Male; Middle Aged; Polypharmacy; Primary Prevention; Research Design; Secondary Prevention; Sodium Chloride Symporter Inhibitors; Time Factors; Treatment Outcome; Valsartan | 2015 |
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial.
Topics: Adult; Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Cardiovascular Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus; Drug Combinations; Enalapril; Female; Humans; Hydrochlorothiazide; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Secondary Prevention; Valsartan | 2019 |
Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial.
Topics: Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Atorvastatin; Cardiovascular Agents; Double-Blind Method; Female; Follow-Up Studies; Heart Diseases; Heart Failure; Humans; Lymphoma; Male; Middle Aged; Retrospective Studies; Stroke Volume; Ventricular Function, Left | 2023 |
24 other study(ies) available for atorvastatin and cardiovascular agents
| Article | Year |
|---|---|
Rhabdomyolysis with concurrent atorvastatin and diltiazem.
Topics: Acute Disease; Acute Kidney Injury; Atorvastatin; Cardiovascular Agents; Chemical and Drug Induced Liver Injury; Diltiazem; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrroles; Rhabdomyolysis | 2002 |
Drug interactions: gasoline and matches.
Topics: Atorvastatin; Cardiovascular Agents; Clinical Trials as Topic; Clopidogrel; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Databases, Factual; Drug Interactions; Heptanoic Acids; Pyrroles; Ticlopidine | 2003 |
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Atorvastatin; Azepines; Captopril; Cardiovascular Agents; Central Nervous System Agents; Chemical and Drug Induced Liver Injury; Chronic Disease; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Heptanoic Acids; Humans; Liver; Liver Diseases; Male; Middle Aged; Pyrroles; Registries; Spain | 2006 |
Atorvastatin therapy associated with improvement in left ventricular remodeling in a case of idiopathic dilated cardiomyopathy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiomyopathy, Dilated; Cardiovascular Agents; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Pyrroles; Ventricular Remodeling | 2006 |
Reducing myocardial injury by minimizing imbalance between oxygen supply and demand.
Topics: Anesthesiology; Animals; Atorvastatin; Blood Pressure; Cardiovascular Agents; Coronary Disease; Dogs; Heart Diseases; Heart Rate; Heptanoic Acids; History, 20th Century; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Ischemia; Myocardial Revascularization; Necrosis; Oxygen; Pyrroles | 2007 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
Reduced intimal hyperplasia in rabbits via medical therapy after carotid venous bypass.
Topics: Administration, Oral; Animals; Atorvastatin; Benzopyrans; Calcium Dobesilate; Cardiovascular Agents; Carotid Stenosis; Clopidogrel; Disease Models, Animal; Ethanolamines; Graft Occlusion, Vascular; Heptanoic Acids; Hyperplasia; Jugular Veins; Male; Nebivolol; Pyrroles; Rabbits; Ticlopidine; Tunica Intima; Vascular Surgical Procedures | 2009 |
The effects of BuYang HuanWu Decoction and its effective components on proliferation-related factors and ERK1/2 signal transduction pathway in cultured vascular smooth muscle cells.
Topics: Alkaloids; Animals; Atorvastatin; Cardiovascular Agents; Cell Cycle; Cell Proliferation; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; Drugs, Chinese Herbal; Dual Specificity Phosphatase 1; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Glycosides; Heptanoic Acids; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Platelet-Derived Growth Factor; Pyrroles; Rats; Rats, Sprague-Dawley; Signal Transduction | 2011 |
A case of recurrent ventricular tachycardia.
Topics: Aged; Atorvastatin; Cardiovascular Agents; Digoxin; Drug Therapy, Combination; Female; Furosemide; Heptanoic Acids; Humans; Isosorbide Dinitrate; Lisinopril; Nitroglycerin; Pyrroles; Recurrence; Tachycardia, Ventricular; Warfarin | 2011 |
Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells.
Topics: Aged; Aged, 80 and over; Antigens, CD; Atorvastatin; beta Catenin; Cardiovascular Agents; Cell Proliferation; Cells, Cultured; Cyclin B; DNA Replication; Dose-Response Relationship, Drug; Drug-Eluting Stents; Endoglin; Heptanoic Acids; Human Umbilical Vein Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Phosphorylation; Pyrroles; Receptors, Cell Surface; Tacrolimus; Time Factors | 2012 |
[Painless myocardial ischemia in patient with extensive constrictive atherosclerosis of coronary arteries].
Topics: Angioplasty; Anticholesteremic Agents; Asymptomatic Diseases; Atorvastatin; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Coronary Vessels; Drug-Eluting Stents; Echocardiography; Electrophysiologic Techniques, Cardiac; Exercise Test; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Myocardial Ischemia; Pyrroles; Severity of Illness Index; Treatment Outcome | 2012 |
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovascular Agents; Clopidogrel; Combined Modality Therapy; Critical Illness; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Middle Aged; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Pyrroles; Recurrence; Registries; Retrospective Studies; Risk Factors; Severity of Illness Index; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Dramatic regression of three-vessel disease under statin treatment in patients with stable angina pectoris.
Topics: Angina, Stable; Atorvastatin; Cardiovascular Agents; Coronary Angiography; Coronary Artery Disease; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Pyrroles; Treatment Outcome | 2012 |
Design of a Dissolving Microneedle Platform for Transdermal Delivery of a Fixed-Dose Combination of Cardiovascular Drugs.
Topics: Administration, Cutaneous; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Newborn; Aspirin; Atorvastatin; Cardiovascular Agents; Chemistry, Pharmaceutical; Drug Combinations; Drug Delivery Systems; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Lisinopril; Microinjections; Platelet Aggregation Inhibitors; Swine | 2015 |
Atorvastatin and sildenafil decrease vascular TGF-β levels and MMP-2 activity and ameliorate arterial remodeling in a model of renovascular hypertension.
Topics: Animals; Aorta; Atorvastatin; Cardiovascular Agents; Collagen; Disease Models, Animal; Drug Combinations; Drug Synergism; Endothelium, Vascular; Gene Expression Regulation; Hypertension, Renovascular; Male; Matrix Metalloproteinase 2; Myocytes, Smooth Muscle; Oxidative Stress; Platelet-Derived Growth Factor; Rats; Rats, Wistar; Reactive Oxygen Species; Signal Transduction; Sildenafil Citrate; Transforming Growth Factor beta; Vascular Remodeling | 2015 |
[Polypill for secondary coronary heart disease prevention].
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Coronary Disease; Drug Combinations; Humans; Medication Adherence; Ramipril | 2015 |
[Combination drug improves adherence].
Topics: Aspirin; Atorvastatin; Capsules; Cardiovascular Agents; Coronary Disease; Drug Combinations; Humans; Ramipril; Secondary Prevention | 2016 |
Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.
Topics: Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Drug Combinations; Humans; Medication Adherence; Ramipril; Salicylic Acid; Secondary Prevention | 2017 |
Postoperative myocardial infarction in an orthognatic jaw surgery.
Topics: Acute Coronary Syndrome; Adult; Anesthesia, General; Angioplasty; Anticoagulants; Atorvastatin; Cardiovascular Agents; Combined Modality Therapy; Disease Susceptibility; Drug-Eluting Stents; Dyslipidemias; Early Diagnosis; Elective Surgical Procedures; Humans; Male; Maxilla; Orthognathic Surgery; Postoperative Complications; Smoking; Surgery, Plastic | 2017 |
Internal Carotid Artery Web as the Cause of Recurrent Cryptogenic Ischemic Stroke.
Topics: Adult; Aspirin; Atorvastatin; Biopsy; Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases; Carotid Artery, Internal; Computed Tomography Angiography; Female; Fibromuscular Dysplasia; Humans; Hyperplasia; Neointima; Recurrence; Risk Factors; Stroke | 2018 |
Aging does not impact drug--drug interaction magnitudes with antiretrovirals.
Topics: Aged; Aged, 80 and over; Aging; Amlodipine; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atorvastatin; Cardiovascular Agents; Cardiovascular Diseases; Darunavir; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rosuvastatin Calcium; Treatment Outcome | 2020 |
Ultraviolet photolysis of four typical cardiovascular drugs: mechanisms, influencing factors, degradation pathways, and toxicity trends.
Topics: Atenolol; Atorvastatin; Bezafibrate; Cardiovascular Agents; Humic Substances; Kinetics; Metoprolol; Photolysis; Ultraviolet Rays; Water Pollutants, Chemical | 2021 |
Effect of the therapy of amiodarone combined with atorvastatin on cardiac function of patients with acute myocardial infarction after percutaneous coronary intervention (PCI).
Topics: Amiodarone; Atorvastatin; Cardiovascular Agents; Case-Control Studies; China; Creatine Kinase, MB Form; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-6; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Random Allocation; Time Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2021 |
Multicomponent spectrophotometric determination of a ternary mixture of widely-prescribed cardiovascular drugs by four different methods.
Topics: Aspirin; Atorvastatin; Cardiovascular Agents; Humans; Ramipril; Spectrophotometry | 2023 |